CYP 7.41% 29.0¢ cynata therapeutics limited

Ann: Investor Presentation, page-546

  1. 831 Posts.
    lightbulb Created with Sketch. 338
    @pfeifer1982

    Yet another thoroughly comprehensive review, thank you. My only query would be:

    Regarding the patent-pending from 2020, surely this would have been provided in the second BLA submission last year, since it appears to meet a reasonable hypothesis of MoA, right? If not, then questions must be asked as to what MSB's management are/were doing.

    So if the FDA have already assessed it as a part of the approval process of Ryoncil, then I keep coming back to the key factor for Ryoncil's approval being the FDA's assessment of the adequacy of the P3 trial. Again, what has made them backflip here?
    Last edited by truss20: 20/06/24
 
watchlist Created with Sketch. Add CYP (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.